TITLE:
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

CONDITION:
Type 2 Diabetes Mellitus

INTERVENTION:
exenatide

SUMMARY:

      This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide
      and insulin glargine (Lantus injection) on beta-cell function in patients with type 2
      diabetes mellitus using metformin.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 30 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes, but otherwise healthy

          -  HbA1c between 6.6% and 9.5%, inclusive.

          -  Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.

          -  Treated with a stable dose of metformin for at least 2 months prior to screening.

        Exclusion Criteria:

          -  Patients previously in a study using exenatide.

          -  Treated with oral anti-diabetic medications other than metformin within 2 months of
             screening (thiazolidinediones within 5 months of screening).

          -  Treated with insulin within 3 months of screening.
      
